MENCARELLI, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 3.769
AS - Asia 2.351
EU - Europa 2.244
SA - Sud America 348
Continente sconosciuto - Info sul continente non disponibili 157
AF - Africa 53
OC - Oceania 2
Totale 8.924
Nazione #
US - Stati Uniti d'America 3.667
SG - Singapore 1.189
UA - Ucraina 418
IE - Irlanda 402
CN - Cina 332
RU - Federazione Russa 310
BR - Brasile 278
HK - Hong Kong 276
IT - Italia 244
SE - Svezia 227
VN - Vietnam 205
DE - Germania 155
FR - Francia 153
FI - Finlandia 137
GB - Regno Unito 67
TR - Turchia 67
KR - Corea 55
IN - India 52
CA - Canada 44
MX - Messico 30
BD - Bangladesh 26
AR - Argentina 23
PL - Polonia 21
IQ - Iraq 19
RO - Romania 19
CH - Svizzera 18
CZ - Repubblica Ceca 18
UZ - Uzbekistan 18
PH - Filippine 17
ES - Italia 15
JP - Giappone 15
EC - Ecuador 14
PK - Pakistan 14
ZA - Sudafrica 14
SA - Arabia Saudita 12
ID - Indonesia 11
CO - Colombia 10
NL - Olanda 9
VE - Venezuela 9
AT - Austria 8
BE - Belgio 8
KE - Kenya 8
GR - Grecia 7
JM - Giamaica 7
CL - Cile 5
ET - Etiopia 5
EU - Europa 5
LB - Libano 5
MA - Marocco 5
MY - Malesia 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
EG - Egitto 4
KG - Kirghizistan 4
LY - Libia 4
PA - Panama 4
PY - Paraguay 4
HN - Honduras 3
JO - Giordania 3
KZ - Kazakistan 3
LT - Lituania 3
QA - Qatar 3
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BO - Bolivia 2
DK - Danimarca 2
DZ - Algeria 2
IL - Israele 2
NG - Nigeria 2
NP - Nepal 2
PE - Perù 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SV - El Salvador 2
AU - Australia 1
BB - Barbados 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LC - Santa Lucia 1
MD - Moldavia 1
MN - Mongolia 1
MZ - Mozambico 1
NI - Nicaragua 1
OM - Oman 1
PW - Palau 1
SC - Seychelles 1
SR - Suriname 1
TH - Thailandia 1
Totale 8.772
Città #
Singapore 894
San Jose 496
Chandler 481
Dublin 402
Hong Kong 276
Ashburn 243
San Mateo 224
Jacksonville 192
Wilmington 150
Dong Ket 144
Boardman 136
Santa Clara 128
Altamura 119
Moscow 107
Medford 100
Princeton 100
Beijing 91
Lawrence 84
Lauterbourg 79
Andover 69
Ann Arbor 66
Perugia 59
New York 48
Izmir 47
Seoul 44
Des Moines 43
Los Angeles 41
Falls Church 35
São Paulo 33
Columbus 29
Saint Petersburg 28
The Dalles 28
Helsinki 24
Munich 22
Phoenix 20
Ho Chi Minh City 17
Norwalk 17
Chennai 16
Orem 16
Rio de Janeiro 15
Tokyo 15
Turku 15
Dallas 14
Piscataway 14
San Paolo di Civitate 14
Stockholm 13
Tashkent 13
Timisoara 13
Warsaw 13
Mexico City 12
Brooklyn 11
Hanoi 11
Houston 11
Manchester 11
Montreal 11
Shanghai 11
Woodbridge 11
Chicago 10
Council Bluffs 10
London 10
Olomouc 10
Toronto 10
Denver 9
Ottawa 9
Boston 8
Brussels 8
Frankfurt am Main 8
Johannesburg 8
New Delhi 8
Baghdad 7
Buffalo 7
Dearborn 7
Nuremberg 7
Ankara 6
Belo Horizonte 6
Bucharest 6
Nairobi 6
Quito 6
San Francisco 6
Seattle 6
Addis Ababa 5
Atlanta 5
Auburn Hills 5
Charlotte 5
Curitiba 5
Guangzhou 5
Guayaquil 5
Jakarta 5
Jeddah 5
Poplar 5
Porto Alegre 5
Queens 5
Rome 5
Americana 4
Bishkek 4
Campinas 4
Da Nang 4
Dammam 4
Dhaka 4
Goiânia 4
Totale 5.647
Nome #
Recombinant galectin-1 prevents experimental colitis in mice via T cell apoptosis. 193
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 148
GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice 143
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. 142
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. 136
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 136
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. 135
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. 131
Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis 131
An NO-derivative of acetaminophen, NCX-701, spares the liver by inhibiting Fas-dependent apoptosis 129
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity 128
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 124
Antiatherosclerotic effect of farnesoid X receptor. 123
4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. 120
3-oxa-lipoxin A4 analog treats colitis induced by Dss by attenuating inflammation and immunity. 119
A beta-oxidation-resistant lipoxin A(4) analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction 116
a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation 114
An essential role of Farnesoid X-Receptor in regulating intestinal fibrosis in murine model of chronic colitis 114
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 110
Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages. 107
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 107
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. 105
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. 105
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 103
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 100
Inhibition of NF-κB by a PXR-dependent pathwaymediates counter-regulatory activities of rifaximin on innate immunity inintestinal epithelial cells. 98
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension 98
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. 97
A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors 97
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. 96
The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. 96
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 96
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation 96
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. 96
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 94
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 93
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 92
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 91
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 91
Proteinase activated receptor (PAR)-2 protects against colitis in mice. Evidence for direct modulation of lamina propria T lymphocytes. 91
A hydrogen-sulfide releasing derivative of mesalamine exhibits markedly enhanced anti-inflammatory effects in experimental colitis 91
FXR an emerging therapeutic target for the treatment of atherosclerosis. 90
Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons 90
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 90
Role of the FXR in Regulating Bile Acid Homeostasis and Relevance for Human Diseases 89
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 89
Epigenetic modulation by methionine deficiency attenuates the potential for gastric cancer cell dissemination. 87
Gene Expression Changes Induced by HIPEC in a Murine Model of Gastric Cancer 86
Nitric oxide protects againist HIV gp 120 endothelial injury. 85
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. 84
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. 83
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 83
IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. 82
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA 82
Critical role of toll-like receptors in modulating GM-CSF activity in rodent models of colitis 82
Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. 81
Proteinase activated receptor (PAR)-2 agonistic peptide protects from Th-1 mediated liver injury in mice. 81
NCX-1000, an NO derivative of UDCA, releases NO and protects against portal hypertension by inhibiting hepatic stellate cell contraction. 80
VLA-1 immunoneutralization protects against colon damage in a mouse model of colitis 80
Farnesoid-X-receptor (FXR) ligands induce a small heterodimer partner (SHP)-dependent upregulation of PPAR-gamma in hepatic stellate cells and in rat model of liver fibrosis. 80
COX-2 selective inhibitors cause gastric damage in aspirin treated rats. Protective effect of nitroaspirin (NCX-4016). 79
NCX-999, a NO-releasing derivative of UDCA, modulates hepatic stellate cells and reduces vasomotor response to nor-epinefrine in intact rats 78
The nuclear receptor SHP (small heterodimer partner) mediates inhibitory effects of farnesoid-X-receptor (FXR) on hepatic stellate cells and protects against liver fibrosis in rodents. 77
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 76
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. 76
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 76
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. 75
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis 75
Inhibition of hydrogen sulfide generation contributes to gastric injury caused byanti-inflammatory nonsteroidal drugs. 74
Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxidereleasing derivative of mesalamine in rodent colitis. 74
The third gas: H2S regulates perfusion pressure in both theisolated and perfused normal rat liver and in cirrhosis. 74
‘The Farnesoid X Receptor Promotes Adipocyte Differentiationd regulates adipose cell function in vivo’ 73
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 73
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 73
The bile acid receptor FXR is a modulator of intestinal innate immunity. 73
H2S Induces Analgesia Is Mediated In Vivo Activation of mu Opioid Receptor and PI3K/AKT Pathway Activation 72
FXR Activation Reverses Insulin Resistance and Protects Against NASH Development 71
The Nuclear Receptor SHP Mediates Inhibition of Hepatic Stellate Cells by FXR and Protects Against Liver Fibrosis 70
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 70
Co-administration of nitric oxide-aspirin (NCX-4016) andaspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. 67
Protective effects of granulocyte macrophage colony stimulating factor (gm-Csf) in Hapten-induced colitis 67
Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide 67
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 66
Celecoxib exacerbates gastrointestinal damage induced by aspirin but not by NO-aspirin (NCX-4016): A randomised, parallel group, blind-observer endoscopic study. Evidence for a protective role of NO in the gastrointestinal mucosa 65
The CCR5 Antagonist Maraviroc Reduces the Potential for Gastric Cancer Dissemination in Rodent Models of Peritoneal Metastasis 65
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. 64
Molecular Determinants of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Model of Peritoneal Gastric Cancer Carcinogenesis 64
The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo 63
Enhanced anti-inflammatory activity of hydrogen sulfide releasing derivative of mesalamine in rodent models of colitis, involves direct inhibition of Nf-kappa B 63
Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis 62
Gastrointestinal safety and anti-inflammatory activity of HCT-1026, NO-releasing flurbiprofen, in healthy humans volunteers 61
Plakilactones from the Marine Sponge Plakinastrella mamillaris. Discovery of a New Class of Marine Ligands of Peroxisome Proliferator-Activated Receptor gamma 60
The bile acid sensor FXR regulates insulin transcription and secretion. 60
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 59
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 59
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 57
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 57
Inhibition of NF-kB by a PXR-Dependent Pathway Mediates Counter-regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells 54
FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis 51
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 48
Totale 8.924
Categoria #
all - tutte 41.168
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.168


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022862 0 152 9 32 32 120 5 274 4 8 75 151
2022/20231.563 116 295 8 154 114 173 1 84 556 0 50 12
2023/2024509 35 67 36 4 4 4 109 36 32 17 104 61
2024/20251.327 10 117 53 46 212 49 28 88 252 76 221 175
2025/20262.893 190 144 176 264 351 256 557 163 426 262 65 39
2026/2027121 51 70 0 0 0 0 0 0 0 0 0 0
Totale 8.924